GDC-0834 10mg 10mg | Purity Not Available
Adooq Bioscience
GDC-0834 is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
More Information Supplier PageGDC-0834 is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
More Information Supplier PagePHCCC is a group I metabotropic glutamate receptor antagonist (IC50 ~ 3 ??M).
More Information Supplier PagePHCCC is a group I metabotropic glutamate receptor antagonist (IC50 ~ 3 ??M).
More Information Supplier PagePHCCC is a group I metabotropic glutamate receptor antagonist (IC50 ~ 3 ??M).
More Information Supplier PagePHCCC is a group I metabotropic glutamate receptor antagonist (IC50 ~ 3 ??M).
More Information Supplier PageSF1126 is a water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities.
More Information Supplier PageSF1126 is a water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities.
More Information Supplier PageSF1126 is a water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities.
More Information Supplier PageGDC-0834 is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
More Information Supplier PageGDC-0834 is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
More Information Supplier Page